RBC cuts Sarepta Therapeutics price target to $17
RBC Capital cut its price target on Sarepta Therapeutics to $17.00 from $19.00, according to Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
U.S. research roundup: analysts revise targets on U.S. companies
Wall Street analysts changed ratings and price targets on several U.S.-listed companies, including Alnylam Pharmaceuticals, Carvana and MongoDB. Reuters compiled the actions in alphabetical order.